Shell Asset Management CO Exelixis, Inc. Transaction History

Shell Asset Management CO

$2.26 Billion
Q1 2024

A detailed history of Shell Asset Management CO transactions in Exelixis, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 21,777 shares of EXEL stock, worth $482,360. This represents 0.02% of its overall portfolio holdings.

Number of Shares

21,777

Previous 22,562 3.48%

Holding current value

$482,360

Previous $541,000 4.44%

% of portfolio

0.02%

Previous 0.02%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$20.17 - $23.93 $15,833 - $18,785	-785 Reduced 3.48%	21,777 $517,000
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $259,278 - $325,006	-13,469 Reduced 37.38%	22,562 $541,000
Q3 2023 Nov 08, 2023	SELL	$19.04 - $22.74 $11,919 - $14,235	-626 Reduced 1.71%	36,031 $787,000
Q2 2023 Jul 28, 2023	SELL	$18.17 - $20.48 $55,854 - $62,955	-3,074 Reduced 7.74%	36,657 $701,000
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $2,249 - $2,678	-138 Reduced 0.35%	39,731 $771,000

Q4 2022 Feb 07, 2023	SELL	$14.96 - $17.39 $124,527 - $144,754	-8,324 Reduced 17.27%	39,869 $639,000
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $197,975 - $281,181	-12,626 Reduced 20.76%	48,193 $756,000
Q2 2022 Aug 09, 2022	BUY	$17.44 - $23.16 $1,831 - $2,431	105 Added 0.17%	60,819 $1.27 Million
Q1 2022 May 04, 2022	SELL	$17.03 - $22.67 $152,946 - $203,599	-8,981 Reduced 12.89%	60,714 $1.38 Million
Q4 2021 Feb 09, 2022	BUY	$15.84 - $21.88 $5,100 - $7,045	322 Added 0.46%	69,695 $1.27 Million
Q3 2021 Nov 04, 2021	SELL	$16.3 - $21.14 $48,574 - $62,997	-2,980 Reduced 4.12%	69,373 $1.47 Million
Q2 2021 Aug 12, 2021	BUY	$17.95 - $25.56 $181,887 - $258,999	10,133 Added 16.29%	72,353 $1.32 Million
Q1 2021 May 10, 2021	BUY	$20.53 - $25.22 $282,266 - $346,749	13,749 Added 28.37%	62,220 $1.41 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $257,018 - $346,604	13,976 Added 40.52%	48,471 $973,000
Q2 2020 Aug 10, 2020	SELL	$16.46 - $27.42 $5,942 - $9,898	-361 Reduced 1.04%	34,495 $819,000
Q1 2020 May 11, 2020	SELL	$14.46 - $21.8 $7,649 - $11,532	-529 Reduced 1.49%	34,856 $600,000
Q4 2019 Feb 13, 2020	SELL	$15.15 - $18.89 $12,892 - $16,075	-851 Reduced 2.35%	35,385 $623,000
Q3 2019 Nov 12, 2019	SELL	$17.68 - $22.65 $5,516 - $7,066	-312 Reduced 0.85%	36,236 $641,000
Q2 2019 Aug 12, 2019	SELL	$18.93 - $24.75 $15,749 - $20,592	-832 Reduced 2.23%	36,548 $781,000
Q4 2018 Feb 13, 2019	SELL	$13.65 - $21.8 $42,315 - $67,580	-3,100 Reduced 7.66%	37,380 $735,000
Q3 2018 Nov 13, 2018	SELL	$15.87 - $22.4 $282,644 - $398,944	-17,810 Reduced 30.55%	40,480 $717,000
Q2 2018 Aug 10, 2018	SELL	$18.56 - $22.45 $146,364 - $177,040	-7,886 Reduced 11.92%	58,290 $1.25 Million
Q1 2018 May 14, 2018	SELL	$22.15 - $31.89 $343,657 - $494,773	-15,515 Reduced 18.99%	66,176 $1.47 Million
Q4 2017 Feb 09, 2018	BUY	$24.23 - $30.93 $222,382 - $283,875	9,178 Added 12.66%	81,691 $2.48 Million
Q3 2017 Oct 20, 2017	BUY	$23.35 - $29.24 $1.69 Million - $2.12 Million	72,513	72,513 $1.76 Million

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.13B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Account

Shell Asset Management CO Exelixis, Inc. Transaction History